Differences in Erythrocyte Magnesium Levels between Men with Schizophrenia Treated with Risperidone and Haloperidol in Prof. Dr. M Ildrem Psychiatric Hospital Medan

Authors

  • Ihsan Fadhilah Department of Psychiatry, Faculty of Medicine, University of North Sumatra, Medan, Indonesia https://orcid.org/0000-0002-0073-3664
  • Bahagia Loebis Department of Psychiatry, Faculty of Medicine, University of North Sumatra, Medan, Indonesia
  • Muhammad Surya Husada Department of Psychiatry, Faculty of Medicine, University of North Sumatra, Medan, Indonesia
  • Nazli Mahdinasari Nasution Department of Psychiatry, Faculty of Medicine, University of North Sumatra, Medan, Indonesia
  • Elmeida Effendy Department of Psychiatry, Faculty of Medicine, University of North Sumatra, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6336

Keywords:

Schizophrenia, Erythrocyte magnesium levels, Risperidone, Haloperidol

Abstract

BACKGROUND: Schizophrenia according to the world health organization is one of the top ten causes of disability in developed countries around the world. Because of the severity, chronicity, and prevalence of schizophrenia, it has a very large economic burden. Magnesium is a micronutrient needed by the body which can affect mental health. Erythrocyte magnesium levels are considered more sensitive than serum magnesium levels to reflect intracellular magnesium status.

AIM: The objective of the study was to determine the differences in erythrocyte magnesium levels between men with schizophrenia who received risperidone and haloperidol treatment at Prof. Dr. M Ildrem Psychiatric Hospital, Medan.

METHODS: This study is an intention to treat and is an experimental pre-test and post-test that compares two groups, namely the intervention group and the control group. The sampling method is non-probability sampling with a consecutive sampling type. The research was conducted at Prof. Dr. M. Ildrem Psychiatric Hospital Medan between July and October 2019. The subjects of the study were 60 men with schizophrenia, namely, 30 who received risperidone and 30 who received haloperidol.

RESULTS: There was a difference in the levels of male erythrocyte magnesium with schizophrenia who received risperidone and haloperidol between the initial week and the third week with a value of p = 0.007. Where there was a higher increase in the haloperidol group which showed a significant difference, namely, p < 0.05.

CONCLUSION: The increase in magnesium levels will improve the symptoms of schizophrenia where magnesium activity decreases glutamate release associated with N-Methyl D-Aspartate receptors and results in the activity of the gamma-aminobutyric acid-ergic system.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Departemen Kesehatan Republik Indonesia. Pedoman Penggolongan dan Diagnosis Gangguan Jiwa di Indonesia III (PPDGJ-III). Jakarta: Departemen Kesehatan Republik Indonesia; 1993. https://doi.org/10.6066/jtip.2013.24.2.121

Kirkpatrick B, Miller B, García-Rizo C, Fernandez-Egea E. Schizophrenia: A systemic disorder. Clin Schizophr Relat Psychoses. 2014;8(2):73-9. https://doi.org/10.3371/csrp.kimi.031513 PMid:23518782

Menteri Kesehatan Republik Indonesia, Peraturan Menteri Kesehatan Republik Indonesia Nomor 54 Tahun 2017 Tentang Penanggulangan Pemasungan Pada Orang Dengan Gangguan Jiwa; 2017. https://doi.org/10.20884/1.jih.2018.4.2.115

Phelan D, Molero P, Martínez-González MA, Molendijk M. Magnesium and mood disorders: Systematic review and meta-analysis. BJPsych Open. 2018;4(4):167-79. https://doi.org/10.1192/bjo.2018.22 PMid:29897029

Noronha JL, Matuschak GM. Magnesium in critical illness: Metabolism, assessment, and treatment. J Crit Care. 2001;15:36-40.

Immanuel S, Iriani A. The reference range of serum, plasma, and erythrocyte magnesium. Med J Indones. 2006;15:229-35. https://doi.org/10.13181/mji.v15i4.246

Nechifor M. Magnesium in psychoses (schizophrenia and bipolar disorders). In: Vink R, Nechifor M, editors. Magnesium in the Central Nervous System. Romania: University of Adelaide Press; 2011. p. 303-12. https://doi.org/10.1017/upo9780987073051.023

Ordak M, Matras J, Muszynska E, Nasierowski T, Bujalska- Zadrozny M. Magnesium in Schizophrenia, Pharmacological Reports, Report No. 44. Poland: Medical University of Warsaw, Department of Pharmacodynamics; 2017. https://doi.org/10.1016/j.pharep.2017.03.022

Gueux E, Duchene-Marullaz P, Rayssiguier Y. Plasma and erythrocyte magnesium levels in a French population. Mag Bull. 1988;10(1):77-80.

Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. Schizophr Bull. 2015;41(6):1397-402. https://doi.org/10.1093/schbul/sbv037 PMid:25841041

Dahlan MS, editor. Statistik Untuk Kedokteran dan Kesehatan. 1st ed. Jakarta: Sagung Seto; 2014.

Association AP, editors. Diagnostic and Statistical Manual and Mental Disorders DSM-5. 5th ed. London: American Psychiatric Publishing; 2013.

Buoli M, Caldiroli A, Panza G, Altamura AC. Prominent clinical dimension, 71 duration of illness and treatment response in schizophrenia: A naturalistic study. Korean Neuropsychiatr Assoc 2012;1(9):354-60. https://doi.org/10.4306/pi.2012.9.4.354

Gogtay N, Vya NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: Perspectives from structural neuroimaging studies. Schizophr Bull. 2011;37(3):504-13. https://doi.org/10.1093/schbul/sbr03 PMid:21505117

Huang J, Chiovenda A, Shao Y, Ma H, Li H, Good MD. Low level of knowledge regarding diagnosis and treatment among inpatients with schizophrenia in shanghai. Neuropsychiatr Dis Treat. 2018;14(1):185-91. https://doi.org/10.2147/ndt.s152917 PMid:29379291

De Pinho LG, Pereira A, Chaves C. Influence of sociodemographic and clinical characteristics on the quality of life of patients with schizophrenia. J Sch Nurs Univ Sao Paulo. 2017;1(1):1-7.

Jahn-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5 Suppl 1:i3-14. PMid:26069819

Severance EG, Prandovszky E, Castiglione J, Yolken RH. Gastroenterology issues in schizophrenia: Why the gut matters. Curr Psychiatry Rep. 2015;17(5):27. https://doi.org/10.1007/s11920-015-0574-0 PMid:25773227

Banskota S, Ghia JE, Khan W. Serotonin in the gut: Blessing or a curse. J Biochim Can. 2018;161:56-64. https://doi.org/10.1016/j.biochi.2018.06.008

Fukuda K. 5-HTP hypothesis of schizophrenia. Med Hypotheses. 2014;82(1):20-3. PMid:24280562

Stahl SM. Psychosis and schizophrenia. In: Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 4th ed. Cambridge: Cambridge University Press; 2013.

Downloads

Published

2021-05-17

How to Cite

1.
Fadhilah I, Loebis B, Husada MS, Nasution NM, Effendy E. Differences in Erythrocyte Magnesium Levels between Men with Schizophrenia Treated with Risperidone and Haloperidol in Prof. Dr. M Ildrem Psychiatric Hospital Medan. Open Access Maced J Med Sci [Internet]. 2021 May 17 [cited 2024 Jul. 23];9(T3):186-92. Available from: https://oamjms.eu/index.php/mjms/article/view/6336

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>